Medication persistence for psoriatic arthritis in a Brazilian real-world setting

• Autor(a) principal: Michael Ruberson Ribeiro da Silva
• Data de Publicação: 2019
• Outros Autores: Jéssica Barreto Ribeiro dos Santos, Alessandra Maciel Almeida, Alexander Itria, Adriana Maria Kakehasi, Juliana Alvares Teodoro, Francisco de Assis Acurcio
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Repositório Institucional da UFMG
• Texto Completo: https://doi.org/10.4155/fsoa-2018-0101; http://hdl.handle.net/1843/56584; https://orcid.org/0000-0003-2550-7249; https://orcid.org/0000-0002-5528-0658; https://orcid.org/0000-0003-0138-9401; https://orcid.org/0000-0001-7500-0230; https://orcid.org/0000-0001-9411-7493; https://orcid.org/0000-0002-0210-0721; https://orcid.org/0000-0002-5880-5261
• topic: Antirheumatic agents; Medication persistence; Psoriatic arthritis; Agentes anti-reumaticos; Medicamentos

Aim: To evaluate the persistence of biological (TNF inhibitor [anti-TNF]) and synthetic (conventional syntheticdisease-modifyingantirheumaticdrugs[csDMARDs])antirheumaticagentsforpsoriaticarthritisand their associated factors. Methods: A historical cohort was developed. Persistence and associated factors wereevaluatedat6and12months.Results:Atotalof161patientswereincluded.Theanti-TNFtreatment presented higher persistence as compared with csDMARDs at 6 (83.4 vs 50.8%; p < 0.05) and 12 months (66.4vs35.6%;p<0.05).Fromanti-TNFs,adalimumabandetanerceptpresentedsimilarpersistence,along with leflunomide and methotrexate among the csDMARDs. The factors associated with non-persistence withregardtoanti-TNFagentswerefemalesexanduseofinfliximab.Conclusion:Anti-TNFagentsareimportanttherapeuticalternativesand presentlowerratesofdiscontinuationascomparedwithcsDMARDs. Lay abstract: Conventional synthetic disease-modifying antirheumatic drugs (csDMARD) and anti-TNF agents were included in the Brazilian National Health System in 2009, yet were not previously the target of evaluations in a Brazilian context. Persistence, that is the time between starting and discontinuing the drug, is a proxy of effectiveness and safety for antirheumatic agents. This study evaluated medication persistence and relevant factors associated with it. Patients using infliximab showed a lower medication persistence when compared with adalimumab and etanercept. The medication persistence with anti-TNF agents was higher when compared with csDMARDs. Female sex and infliximab were predictors of medication non-persistence.